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Nonalcoholic fatty liver disease (NAFLD) is an umbrella 
term that is used to describe a variety of conditions charac-
terized by a build-up of fat within liver cells. NAFLD can 
range from mild hepatic steatosis [nonalcoholic fatty liver 
(NAFL)] to the more severe nonalcoholic steatohepatitis 
(NASH), and can progress to fibrosis, cirrhosis, and hepa-
tocellular carcinoma. NAFLD is the predominant cause of 
chronic liver disease in many parts of the world, and is 
present in 75–90% of adults who are morbidly obese (1, 2). 
Given that the liver is a central regulator of whole-body 
energy homeostasis, it is not surprising that many individu-
als with NAFLD are also characterized by metabolic com-
plications, including insulin resistance, muscle atrophy, 
and cardiovascular disease, resulting in increased morbid-
ity and mortality (3).
NAFL is diagnosed when liver fat exceeds 5% of the total 
liver weight. Lipid accumulation in the liver is regulated by 
the interplay between the delivery of lipids to the liver and 
their hepatic uptake, synthesis, oxidation, and secretion of 
lipids. Alterations in the equilibrium of one or more of 
these processes can promote hepatic steatosis (4). NASH is 
characterized by hepatic steatosis, hepatocyte ballooning, 
and lobular inflammation. The mechanisms that trigger 
hepatic inflammation are poorly understood, and to date, 
a liver biopsy is the only reliable method to distinguish be-
tween the different stages of NAFLD. Several studies have 
tried to identify lipid biomarkers of NAFL and NASH, but 
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this has proven to be very difficult because the correlations 
between blood and liver lipid species drastically decrease 
after the transition from NAFL to NASH (5). We previously 
used lipidomics to compare serum lipid profiles from ex-
cessive chronic drinkers without liver disease to those with 
advanced alcoholic cirrhosis, and showed that circulating 
lipids associate with alcoholic liver cirrhosis and represent 
potential biomarkers for risk assessment (6). The aim of 
the current study was to gain a more comprehensive under-
standing of the hepatic and plasma lipidomic changes in 
morbidly obese subjects with NAFL or NASH compared 
with morbidly obese subjects without NAFLD, and to gain 
insight into lipid species that are linked to disease progres-
sion through the different stages of NAFLD. We performed 
lipidomic analysis in liver biopsies and plasma samples 
from 58 subjects classified on the basis of liver histology as 
either normal (n = 16), steatotic (n = 10), or NASH (n = 32).
MATERIALS AND METHODS
Study cohort
Our study cohort consisted of 58 subjects with severe obesity 
(BMI >35) who underwent bariatric surgery. The institutional 
medical ethical committee of Maastricht University approved the 
study, and all subjects gave written informed consent before par-
ticipation in the study. Just before surgery, a fasting venous blood 
sample was obtained from each subject. During surgery, a fasted 
liver biopsy was obtained. Part of the liver biopsies were fixed in 
formalin and embedded in paraffin, and histopathology was per-
formed by H&E staining and Masson’s trichrome staining. Sub-
jects were classified as control (CTRL), NAFL, or NASH according 
to the criteria of both Brunt et al. (7) and Kleiner et al. (8). The 
CTRL group was comprised of subjects showing <5% steatotic he-
patocytes. The steatotic group was comprised of individuals show-
ing >5% steatotic hepatocytes without significant inflammation, 
as observed after H&E staining (no intra-acinar inflammatory foci 
per 20 fields with a 20 ocular and no portal tract inflammation). 
The third group was comprised of subjects with NASH, who were 
identified by the presence of steatosis, lobular inflammation, and 
hepatocellular ballooning.
Sample preparation and lipid extraction
Lipid extraction of the liver and plasma was carried out using 
an earlier described single-phase chloroform:methanol (2:1) ap-
proach, with some modifications (9). Briefly, liver tissues (weigh-
ing 0.7–1.9 mg) were first homogenized with a Bullet Blender® 
Gold homogenizer (Next Advance, Inc., Averill Park, NY) in 
250 l Tris-NaCl containing 100 M of butylhydroxytoluene, and 
then underwent further probe sonication (S-4000, Misonix Ultra-
sonic, amplitude 26, 30 s on ice; Misonix) to break down the tissue 
completely. For lipid extraction, a 10 l liver or plasma sample 
was mixed with 200 l of chloroform/methanol (2:1 v/v) and 
10 l of internal standard mix (supplemental Table S1). The sam-
ples were rotary mixed and sonicated for 30 min at room tempera-
ture, then centrifuged (16,000 g, 15 min) to remove the insoluble 
pellets. The supernatants were then transferred to 96-well plates 
and dried using the Speedy Vac system (Savant RVT5105; Thermo 
Fisher Scientific). Prior to lipidomic analysis, the lipid extract was 
dried and redissolved in 50 l of water-saturated butanol. Then, 
50 l of methanol containing 10 mM ammonium formate were 
added. The samples were subsequently centrifuged (3,350 g, 
5 min, room temperature), and the supernatant containing the 
reconstituted lipids was transferred to glass vials (with glass in-
serts) for LC-MS lipidomic analysis.
Lipid profiling
Targeted lipidomics for the liver and plasma specimens was 
performed using LC coupled with an electrospray ionization 
Qtrap 4000 mass spectrometer (AB Sciex), as described earlier 
with slight modifications (10). HPLC separation was conducted 
using an Agilent 1200 series HPLC system with a Poroshell 120 
EC-C18 column (2.1 × 100 mm, 2.7 microns; Agilent) with the 
thermostat set at 50°C. The solvent system consisted of solvent A 
[60% water, 20% methanol, and 20% THF (v/v/v) with 10 mM 
ammonium formate] and solvent B [75% THF, 20% methanol, 
and 5% water (v/v/v) with 10 mM ammonium formate]. Our gra-
dient was as follows: starting conditions at 90% A 10% B, increas-
ing to 20% B over 0.1 min then increasing to 35% B at 3 min, 50% 
B at 3.5 min, 62% B at 11 min, followed by a sharp adjustment to 
89% B at 11.1 min with a shallow gradient to 92% B at 14.9 min 
then adjusting to 100% B at 15 min and holding until 16.5 min. 
The gradient was then adjusted back to starting conditions at 
17 min and held for 3 min for a final run time of 20 min. This 
method enabled all lipid species, including diacylglycerol (DG) 
and triacylglycerol (TG) species, to be monitored in a single chro-
matographic run. As in the previous method, the quantification of 
the TG species was based on the neutral loss of a FA (+NH4) and 
the remaining FAs were assigned based on comprehensive neutral 
loss scans of each FA type using the pooled plasma quality control 
sample. Thus, we were able to differentiate the TG species con-
taining 17:0 acyl chains (e.g., TG(16:0_17:0_18:1) from the inter-
nal standard [TG(17:0/17:0/17:0)] based on precursor mass (m/z 
864.8 and m/z 866.8), the neutral loss [299.3 Da (18:1) and 287.2 
Da (17:0)], and the retention time (15.65 min and 15.94 min). A 
total of 474 lipid species across 29 lipid classes and subclasses were 
detected in this study (supplemental Table S1). AB Sciex Multi-
quant software version 2.1.1 (AB Sciex) was used for quantifica-
tion of peaks and data integration.
Phospholipid isomer characterization
Under normal analysis conditions, we were unable to obtain 
phospholipid acyl composition. However, our current chroma-
tography allowed separation of isomers by their retention time. 
To facilitate identification, the FA composition of phospholipids 
was characterized by either collision-induced dissociation in nega-
tive ionization mode, for neutral or negatively charged species, or 
by collision-induced dissociation of lithium adducts in positive 
ionization mode for positively charged species, and subsequently 
used to infer structural composition of phospholipid isomers 
based on retention time for species that were well separated. 
Characterization of the phospholipid FAs was performed on 
whole lipid extracts of pooled plasma samples. For the analysis of 
lithium adducts of phosphatidylcholine (PC), alkylphosphatidyl-
choline, alkenylphosphatidylcholine, and SM, the 10 mM of am-
monium formate in the extraction buffer and running solvents 
were substituted with 200 M of lithium acetate, which provided 
the ability to monitor for lithium adducts for additional structural 
information (11, 12). Where it was not possible to definitively 
characterize isomers (typically resulting from double bond posi-
tion), we adopted the system of annotating with an (a) and a (b).
Statistical analysis
Patient characteristics are presented as mean ± SEM (numeri-
cal data) or percent (categorical data). For 15 out of 18 character-
istics shown, there was at least one missing data point (maximum 
seven missing for any characteristics), and they were estimated 
with the imputation approach. The missing data were imputed 
using the multiple imputation by chained equations (MICE) 
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method, utilizing the R package “mice”. The numerical data were 
analyzed with the Mann-Whitney U test, while the categorical data 
were analyzed with the 2 test. A P value <0.05 was considered 
significant. The liver and plasma lipidomic data are presented as 
picomoles per micromole of PC. Mean ± SEM or percent differ-
ence to the CTRL group are used to display the lipidomic data. 
The Kruskal-Wallis test corrected with the Benjamini-Hochberg 
approach was used to determine the inter-group significance. A 
corrected P value <0.05 was considered significant. Mann-Whitney 
U tests corrected with the Dunn-Sidak approach were utilized as 
the post hoc test, and a P value <0.05 was considered significant. 
To determine the association of the lipid species or classes to the 
disease (i.e., NAFL and NASH), logistic regression was performed 
between CTRL, NAFL, and NASH. The Benjamini-Hochberg ap-
proach was applied for multiple comparisons, and a P value <0.05 
was considered significant.
RESULTS
Patient characteristics
Patients undergoing bariatric surgery were retrospec-
tively grouped into CTRL (n = 16), NAFL (n = 10), and 
NASH (n = 32), as determined by histological examinations 
of their liver biopsies. All subjects were morbidly obese and 
most subjects complied with the definition of metabolic 
syndrome [i.e., large waist circumference (>89 cm for 
women and >102 cm for men, hyperglycemia (fasted glu-
cose >5.6 mmol/l), hypertriglyceridaemia (>1.7 mmol/l), 
and reduced HDL cholesterol (<1.3 mmol/l in women and 
<1.04 mmol/l in men)]. Homeostatic model assessment of 
insulin resistance (HOMA-IR) (5.50 ± 0.51 vs. 3.06 ± 0.34) 
and blood glucose levels (6.9 ± 0.4 vs. 5.7 ± 0.3) were in-
creased in NASH compared with CTRL, indicating a more 
insulin-resistant state. As expected, aspartate aminotrans-
ferase levels were higher in NASH compared with CTRL. 
When comparing NAFL to NASH, only glucose levels were 
significantly higher in individuals with NASH (Table 1).
Differences in hepatic lipid classes and species between 
CTRL, NAFL, and NASH
To investigate the hepatic lipidome in individuals with 
NAFL and NASH, the abundance of each lipid class was 
expressed relative to the CTRL group, with CTRL values 
set at 100%. Levels of TG, DG, acylcarnitine, dihydrocer-
amide, dihexosylceramide, cholesterol, cholesteryl ester 
(CE), cardiolipin, and ubiquinone were significantly in-
creased in NAFL and/or NASH groups compared with 
CTRL. Only acylcarnitine and dihexosylceramide were sig-
nificantly higher in the NASH group compared with the 
NAFL group (Fig. 1, supplemental Table S2).
FA composition of TG and DG
Storage of excessive energy as TG is a feature and a key 
diagnostic criterion of NAFLD. Many of the TG and DG 
species were higher in the NAFL and NASH groups com-
pared with the CTRL group. In the NASH group, nearly all 
TG, but not DG, species were significantly higher com-
pared with the NAFL group (supplemental Table S3). To 
better understand changes in the FA composition of TGs 
and DGs between groups, FA composition was calculated 
as a percentage of total FAs of each lipid class (Fig. 2). In-
dividuals with NASH had significantly more saturated FAs 
(SFAs) (i.e., 14:0 FA, 17:0 FA, and 18:0 FA) in their TGs 
compared with the CTRL group (Fig. 2A), whereas the 
most abundant SFA (16:0) did not change. The percentage 
of polyunsaturated arachidonic acid (20:4 FA) in TG was 
progressively lower in accordance with NAFLD severity. In-
terestingly, the percentage of docosahexaenoic acid (22:6 
FA), which is another PUFA in TG, did not differ signifi-
cantly between the groups (Fig. 2B). Although total levels 
of DG increased to a similar extent as TG with NAFL and 
NASH, there were disparities between the two lipid classes 
in terms of FA composition. Individuals with NAFL and 
NASH had higher levels of MUFAs in their DGs (16:1 FA 
and 18:1 FA). In contrast, percentages of SFA (18:0 FA), 
diunsaturated (DUFA, 18:2 FA), and long-chain PUFAs 
(20:4, 22:5, and 22:6) declined in the DG pool of the NAFL 
and NASH groups (Table 2, Fig. 2C, D).
FA composition of CEs
Like TGs and DGs, certain CEs comprised lipid species 
that were more abundant in the NAFL and NASH groups 
compared with the CTRL group (Fig. 1; supplemental 
Tables S2, S3). Among the most abundant FAs in CEs, 16:1 
FA and 18:2 FA were increased in subjects with NASH com-
pared with CTRL, while levels of 16:0 FA and 18:1 FA were 
decreased. The 16:0 FA was also significantly lower in NAFL 
individuals compared with CTRL (Fig. 3A). With respect to 
the less abundant FAs, 16:2 FA, 17:1 FA, 18:3 FA, and 22:6 
FA were increased in the NASH group as compared with 
the CTRL group, while 20:1 FA, 20:2 FA, and 22:4 FA were 
decreased. The 16:2 FA was also significantly higher in the 
TABLE 1. Subject characteristics
Characteristics
Group
CTRL NAFL NASH
Number 16 10 32
Sex (% female) 81.3 90.0 65.6
Age (years) 42.3 ± 2.5 41.6 ± 3.9 45.5 ± 1.8
BMI (kg/m2) 41.0 ± 1.6 45.5 ± 2.4 48.39 ± 1.9
Type II diabetes (%) 6.3 20.0 34.4
Glucose (mmol/l) 5.7 ± 0.3 5.6 ± 0.3 6.9 ± 0.4a,b
Insulin (mU/l) 12.3 ± 1.3 20.0 ± 3.5 18.8 ± 1.9
HOMA-IR 3.06 ± 0.34 4.96 ± 0.76 5.50 ± 0.51a
HbA1c (%) 6.1 ± 0.2 6.5 ± 0.4 6.9 ± 0.2
Total cholesterol (mmol/l) 4.74 ± 0.22 5.20 ± 0.31 4.97 ± 0.19
HDL cholesterol (mmol/l) 1.13 ± 0.09 0.95 ± 0.08 1.02 ± 0.08
LDL cholesterol (mmol/l) 2.76 ± 0.21 3.30 ± 0.36 2.99 ± 0.17
TG (mmol/l) 1.87 ± 0.24 1.98 ± 0.32 2.22 ± 0.21
Free FA (mmol/l) 0.51 ± 0.06 0.59 ± 0.12 0.92 ± 0.19
ALT (U/l) 19.9 ± 1.2 25.3 ± 2.9 28.6 ± 2.5
AST (U/l) 15.3 ± 1.9 17.9 ± 2.5 28.2 ± 2.2c
CRP (mg/l) 9.4 ± 2.1 16.3 ± 5.7 9.6 ± 1.0
Baseline characteristics of CTRL, NAFL, and NASH groups are 
shown as percent (for categorical data) and mean ± SEM (for nominal 
data). Data were analyzed using the chi-square test (categorical) or 
Mann-Whitney U test (nominal). HbA1c, hemoglobin A1c; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; CRP, 
C-reactive protein.
aP < 0.05 versus CTRL.
bP < 0.05 versus NAFL.
cP < 0.01 versus CTRL.
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NAFL group compared with CTRL and 20:2 FA was signifi-
cantly lower in NASH compared with NAFL (Fig. 3B, C).
Phospholipids and sphingolipids
In contrast to TGs, DGs, and CEs, there were only a few 
differences among the phospholipid and sphingolipid 
species between groups (supplemental Tables S2, S3). 
Notably, several phospholipid species comprising docosa-
hexaenoic acid (22:6 FA) were significantly lower when 
comparing individuals with NAFL and NASH, including 
PC(P-16:0/22:6)(a) (NASH vs. NAFL), LPC 22:6[sn2] (NASH 
vs. CTRL), and PE(18:1_22:6)(a) (NASH vs. CTRL and 
NASH vs. NAFL). Furthermore, PC(40:7) and PC(40:8), 
which both contained 22:6 FA, were also lower in individu-
als with NASH compared with CTRL (Fig. 4A, supplemen-
tal Table S3). Although significant inter-group differences 
were not observed in any of the individual odd-chain PC 
species, logistic regression analysis indicated that total odd-
chain PC was negatively associated with NAFLD. The odds 
ratio of total odd-chain PC, NASH versus CTRL, was 0.40 
and reached statistical significance (Fig. 4A, B).
Fig. 1. Hepatic lipid abundance of the lipid classes/
subclasses within the CTRL, NAFL, and NASH groups. 
Hepatic lipid abundance of the measured lipid classes 
and subclasses of NAFL (gray bars) and NASH (black 
bars) groups were compared with the CTRL (white 
bars) group and the result is presented as relative per-
cent to CTRL. In panel A, the abundance of TG and 
DG are shown, and the rest of the lipid classes are 
shown in panel B. All values are expressed as mean ± 
SEM. Data were analyzed with the Kruskal-Wallis test 
and corrected for multiple comparisons with the Ben-
jamini-Hochberg approach. The Mann-Whitney U test 
corrected with the Dunn-Sidak approach was used for 
the post hoc analysis (n = 16 for CTRL; n = 10 for 
NAFL; n = 32 for NASH). *P < 0.05, **P < 0.01, ***P < 
0.001 versus CTRL; #P < 0.05, ##P < 0.01 versus NAFL.
Fig. 2. FA composition of hepatic TG and DG in the 
CTRL, NAFL, and NASH groups. FAs comprising he-
patic TG (A, B) and DG (C, D) are shown as the per-
cent of total FA of the respective lipid classes in the 
CTRL (white bars), NAFL (gray bars), and NASH 
(black bars) groups. The FAs with high and low abun-
dance in TG are presented in A and B, while the FAs 
with high and low abundance in DG are presented in 
C and D. All values are expressed as mean ± SEM. Data 
were analyzed with the Kruskal-Wallis test and cor-
rected for multiple comparisons with the Benjamini-
Hochberg approach. The Mann-Whitney U test 
corrected with the Dunn-Sidak approach was used for 
the post hoc analysis (n = 16 for CTRL; n = 10 for 
NAFL; n = 32 for NASH). *P < 0.05, **P < 0.01, *** P < 
0.001 versus CTRL; #P < 0.05, ##P < 0.01 versus NAFL.
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In the sphingolipids class, only dihydroceramide and di-
hexosylceramide were significantly different between the 
CTRL and NAFLD groups. Interestingly, although both 
classes of sphingolipids were higher in individuals with 
NASH compared with CTRL, levels of dihydroceramide 
accumulated progressively with the disease severity (signifi-
cant difference between NASH vs. CTRL), while levels of 
dihexosylceramide were only increased in the NASH group 
(significant NASH vs. CTRL and NASH vs. NAFL) (Fig. 1, 
supplemental Table S2). In line with its respective lipid 
class, the dihydroceramide species, Cer(d18:0/18:0), was 
increased in the NAFL and NASH group compared with 
CTRL, while the dihexosylceramide species, Hex2Cer(d18:1/ 
18:0) and Hex2Cer(d18:1/24:1), were only increased in 
the NASH group. The only SM species that differed 
between the groups was SM(38:1), which was lower in 
the NASH group compared with CTRL (supplemental 
Table S3).
Mitochondrial lipids and their FA composition in NAFLD
Mitochondrial dysfunction has been suggested to play 
a pivotal role in the pathogenesis of NAFLD (13, 14). 
Cardiolipin, acylcarnitine, and ubiquinone are lipid 
classes that have been linked to mitochondrial function 
(15, 16). Unlike other phospholipid classes, cardiolipin 
levels were significantly higher in the NAFL and NASH 
groups, as compared with the CTRL group (Fig. 1). 
When the FA composition of cardiolipin was analyzed, 
the percentage of 18:2 FA, the most abundant FA in the 
cardiolipin pool, was lower in NASH (not significant un-
der Kruskal-Wallis test; Dunn-Sidak corrected Mann-
Whitney U test P value = 0.039). The percentage of 
MUFAs was increased in NASH, while the percentage of 
diunsaturated FAs (DUFAs) was decreased (supplemental 
Table S4).
Nearly all acylcarnitine FAs were increased in individu-
als with NASH (supplemental Table S3). However, there 
were no differences in acylcarnitine FA composition be-
tween groups when expressed as a percentage of the total 
(supplemental Table S4). Some FAs showed a trend 
toward significance. Specifically, acylcarnitine 18:1 was 
increased in NASH compared with CTRL (not significant 
under Kruskal-Wallis test; Dunn-Sidak corrected Mann-
Whitney U test P value = 0.015, NASH vs. CTRL), while 
acylcarnitine 18:2 was decreased in NASH versus CTRL 
(not significant under Kruskal-Wallis test; Dunn-Sidak 
TABLE 2. Comparison of the FA saturation levels within the selected 
lipid classes between CTRL, NAFL, and NASH groups
CTRL NAFL NASH
TG
 SFA 40.3 ± 0.66 41.4 ± 1.11 43.1 ± 0.50a 
 MUFA 48.8 ± 0.57 48.3 ± 0.48 47.7 ± 0.42
 DUFA 10.7 ± 0.62 10.2 ± 0.74 9.1 ± 0.37
 PUFA 0.20 ± 0.02 0.16 ± 0.02 0.14 ± 0.01a
DG
 SFA 39.4 ± 0.89 36.0 ± 1.47b 36.5 ± 0.92
 MUFA 38.5 ± 1.70 47.5 ± 1.26a 50.1 ± 1.00c
 DUFA 12.0 ± 0.64 10.1 ± 0.86 9.10 ± 0.48a
 PUFA 10.0 ± 0.84 6.38 ± 0.66b 4.36 ± 0.17c,d
CE
 SFA 35.2 ± 0.69 32.8 ± 0.83 29.7 ± 0.60c,d
 MUFA 25.1 ± 0.91 22.7 ± 0.92 21.8 ± 0.80b
 DUFA 32.3 ± 1.08 35.9 ± 1.06 38.9 ± 1.11a
 PUFA 7.32 ± 0.49 8.61 ± 0.56 9.59 ± 0.36a
Cardiolipin
 SFA 0.26 ± 0.05 0.38 ± 0.16 0.41 ± 0.08
 MUFA 11.5 ± 0.44 12.8 ± 1.55 12.8 ± 0.36b
 DUFA 87.4 ± 0.47 86.0 ± 1.70 86.0 ± 0.38b
 PUFA 0.83 ± 0.08 0.76 ± 0.07 0.81 ± 0.06
Acylcarnitine
 SFA 62.7 ± 3.65 52.3 ± 4.69 57.9 ± 2.63
 MUFA 25.0 ± 3.68 32.0 ± 3.97 36.0 ± 2.45b
 DUFA 12.3 ± 2.58 15.7 ± 4.85 6.19 ± 0.88
 PUFA — — —
Data in each lipid class are shown as mean ± SEM and were analyzed 
with the Kruskal-Wallis test and corrected for multiple comparisons with 
the Benjamini-Hochberg approach. The Mann-Whitney U test corrected 
with the Dunn-Sidak approach was the post hoc analysis (n = 16 for 
CTRL; n = 10 for NAFL; n = 32 for NASH).
aP < 0.01 versus CTRL.
bP < 0.05 versus CTRL.
cP < 0.001 versus CTRL.
dP < 0.05 versus NAFL.
Fig. 3. FA composition of hepatic CE in the CTRL, 
NAFL, and NASH groups. FAs comprising hepatic CE 
are shown as the percent of total FA of the lipid class in 
the CTRL (white bars), NAFL (gray bars), and NASH 
(black bar) groups. Panels A, B, and C present the FAs 
with high, low, and medium abundance, respectively. 
All values are expressed as mean ± SEM. Data were 
analyzed with the Kruskal-Wallis test and corrected for 
multiple comparisons with the Benjamini-Hochberg 
approach. The Mann-Whitney U test corrected with 
the Dunn-Sidak approach was used for the post hoc 
analysis (n = 16 for CTRL; n = 10 for NAFL; n = 32 for 
NASH). *P < 0.05, **P < 0.01, ***P < 0.001 versus 
CTRL; #P < 0.05.
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corrected Mann-Whitney U test P value = 0.082, NASH vs. 
CTRL) (supplemental Table S4). Levels of ubiquinone were 
increased with NAFL and NASH, compared with CTRL 
(Fig. 1).
NAFLD plasma lipidomics and its relationship to the 
hepatic lipidome
Several earlier studies examined the potential of predict-
ing NAFLD by measuring plasma lipids (17, 18). However, 
none of the lipid biomarkers have been widely recognized 
as strong or reliable predictors to assess NAFLD in clinical 
settings. To investigate the possibility and accuracy of de-
tecting NAFLD by assessing plasma lipids, we performed 
plasma lipid profiling using plasma samples from the 
CTRL, NAFL, and NASH subjects. The results were ana-
lyzed using logistic regression. Interestingly, acylcarnitines 
were the only plasma lipids that were significantly different 
between groups; more specifically, it was shown that acyl-
carnitines were increased in NASH versus CTRL subjects 
(Table 3, supplemental Tables S5, S6).
To determine how well plasma and hepatic lipidomes 
correlated, we performed Pearson correlations between 
the two datasets. While many plasma and hepatic lipid spe-
cies correlated significantly, most of the highly correlated 
lipid species belonged to phospholipid classes (PC, alkyl-
phosphatidylcholine, alkenylphosphatidylcholine, lyso-
phosphatidylcholine, phosphatidylethanolamine, and 
phosphatidylinositol) and SM. Total acylcarnitine showed 
a high and positive correlation between the plasma and he-
patic lipidomes (supplemental Tables S7, S8). Weaker, but 
significant, positive correlations were also found for dihy-
droceramides, monohexosylceramides, SMs, alkylphospha-
tidylcholines, phosphatidylserines, and TGs.
DISCUSSION
The hepatic and plasma lipidome changes extensively 
with the development of obesity and NAFLD, as demon-
strated by earlier lipidomic studies (17–21). With a refined 
lipidomic platform, our study not only covered the most 
Fig. 4. Hepatic PC composition in the CTRL, NAFL, 
and NASH groups and the relationship of odd-chain 
PC to NAFLD. A: Heat map presentation of the fold 
differences in the PC species between the CTRL, 
NAFL, and NASH groups. B: The associations of total 
odd-chain PC to NAFLD, using logistic regression. To-
tal odd-chain species were summed and log trans-
formed before normalization to the interquartile 
ranges. The logistic regression was subsequently per-
formed on NAFL versus CTRL (white), NASH versus 
CTRL (gray), and NASH versus NAFL (black). The 
data are shown as odds ratios and the error bars as the 
95% confidence intervals. *P < 0.05; **P < 0.01.
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common and abundant lipids, but also several low abun-
dance and less studied lipid classes and species. Impor-
tantly, several classes/subclasses of lipids that differed 
significantly between the CTRL, NAFL, and NASH groups 
are related to mitochondrial dysfunction, a process that 
has been suggested to play an important role in the devel-
opment of NAFLD. This study describes how hepatic and 
plasma lipid profiles are altered with NAFLD and high-
lights the possible implications of these changes on mito-
chondrial function and the progression of NAFLD.
In the current study, we found increased hepatic levels 
of TG, DG, CE, and free cholesterol in individuals with 
NAFLD, which is in congruence with earlier studies (19, 20). 
Also, the fatty acyl composition of these lipid classes was 
largely similar to earlier reports; there was a progressive de-
crease in percent PUFA in TGs and DGs, an increase in 
percent PUFA within CE, and an accumulation of free cho-
lesterol in the NAFL and/or NASH groups. Furthermore, 
several PUFA-containing phospholipid species, especially 
those with docosahexanoic acid (22:6, n-3), decreased sig-
nificantly in the NAFLD groups, which is again in line with 
studies reporting an increased n-6/n-3 ratio in NAFLD 
livers (19, 20).
Several recent studies suggest that mitochondrial dys-
function plays a key role in the development of advanced 
NAFLD. Hepatocytes are rich in mitochondria (500–
4,000 mitochondria per hepatocyte) (22), and mitochondrial 
abnormalities associated with NAFLD include abnormal 
morphological changes, leaking mitochondria, and oxida-
tive stress (14, 23). In an elegant study by Koliaki et al. (14), 
it was recently shown that individuals with NAFL had 
5-fold higher hepatic mitochondrial respiration. Inter-
estingly, this compensatory adaptation was abolished in 
BMI-matched individuals with NASH. The authors proposed 
that increased lipid availability in the liver of individuals 
with NAFL stimulates hepatic mitochondrial capacity and 
thereby serves to protect against NAFLD progression. How-
ever, increased respiration may not be bioenergetically 
efficient due to leaking mitochondria and may promote 
excessive hepatic oxidative stress, challenging hepatocellu-
lar antioxidant defense mechanisms. Once these mecha-
nisms fail, mitochondrial functionality decreases, resulting 
in the development of NASH (14).
Cardiolipin, ubiquinone, and acylcarnitine play an im-
portant a role in mitochondrial function. Cardiolipin is a 
phospholipid that is required for optimal mitochondrial 
function (15). It is located in the inner mitochondrial 
membrane, where it interacts with and stabilizes mitochon-
drial enzymes and plays a role in maintaining inner mem-
brane fluidity and osmotic stability (24). Cardiolipin is also 
important for mitochondrial biogenesis and the assembly 
of respiratory enzyme supercomplexes (25). Ubiquinone, 
also known as coenzyme Q10, is highly abundant in mito-
chondria (26). It is involved in the regulation of mito-
chondrial functions, such as membrane transition pore 
permeability and the activation of uncoupling proteins, 
and it acts as an anti-inflammatory agent and a lipophilic 
antioxidant protecting lipids, protein, and DNA from 
oxidation (16). Acylcarnitine is an intermediate, which is 
transported through the mitochondrial inner membrane 
and subsequently releases its attached fatty acyl group for 
-oxidation (27).
Our study shows that hepatic cardiolipin and ubiqui-
none accumulated in NAFL, but did not increase further 
with NASH. Ferreira et al. (28) also observed increased 
levels of hepatic cardiolipin and ubiquinone in two dia-
betic rat models (Goto-Kakizaki and STZ-induced). Inter-
estingly, both models of diabetes also presented a decreased 
susceptibility of liver mitochondria to the induction of 
mitochondrial permeability transition, a pore-opening re-
action that is triggered by calcium and oxidative stress that 
leads to mitochondrial swelling and cell death. The authors 
suggested that the increase in cardiolipin and ubiqui-
none were compensatory processes aimed at preserving 
mitochondrial bioenergetic function (28). Similarly, we 
propose that the increased levels of cardiolipin and ubiqui-
none observed here are indicative of enhanced mitochon-
drial function, which may be invoked to maintain or boost 
mitochondrial function in response to the excessive energy 
substrate availability and/or hepatic insulin resistance. In 
support of this hypothesis, recent studies in rats with 
NAFLD found increased liver cardiolipin levels (29, 30), 
and these levels correlated positively to in vitro measures of 
mitochondrial membrane potential and respiration (30). 
Furthermore, increased mitochondrial respiration has pre-
viously been observed in patients with hepatic steatosis 
(14). Importantly though, excess cardiolipin has also been 
shown to have detrimental effects on mitochondria. Car-
diolipin is highly susceptible to peroxidation due to its 
close association with respiratory chain proteins, which 
may result in induction of the apoptotic cascade that ulti-
mately leads to programmed cell death (31–33). Indeed, 
cardiolipin peroxidation is associated with mitochondrial 
dysfunction in several pathophysiological conditions, in-
cluding NAFLD (30–33). We also observed an increase in 
cardiolipin MUFA percent and a decrease in DUFA percent 
(mostly linoleic acid, C18:2). Similar alterations in cardiolipin 
TABLE 3. Plasma lipid species as potential predictors of NAFLD
NAFL versus CTRL NASH versus CTRL NASH versus NAFL
OR >1 SM(41:1) Acylcarnitine 12:0 Hex3Cer(d18:1/22:0)
SM(42:1) Acylcarnitine 14:1 SM(36:2)(a)
Ubiquinone Acylcarnitine 14:2 SM(38:1)
Acylcarnitine 16:1 SM(41:1)
PE(P-16:0/22:4) SM(42:2)(b)
CE(16:1) PC(20:0_20:4)
CE(17:1)
OR <1 PC(35:2)(a) PC(18:0_22:5)(a)
PC(17:0_22:6)(a) PI(40:5)(a)
PC(40:7)
PC(40:8)
LPC 17:0[sn2]
PE(O-40:6)
LPE 16:0[sn2]
PI(40:5)(a)
Data of CTRL, NAFL, and NASH groups were analyzed pairwise 
with logistic regression. Only lipid species with significant (P < 0.05) 
uncorrected Ps are listed here. The (a) and (b) behind the lipid names 
of some species indicate that the lipid is one of the structural isomers 
separated by LC, but with an undetermined full chemical structure. 
Lipid species are categorized by the values of their odds ratios (OR).
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composition have previously been shown to compromise 
mitochondrial function by disrupting the highly symmet-
ric FA distribution (i.e., identical FAs are often found in 
both sn-1 positions and in both sn-2 positions) and have 
also been linked to Barth syndrome, a childhood onset of 
dilated cardiomyopathy and neutropenia associated with 
mitochondrial respiratory chain dysfunction (15, 34, 35). It 
is also relevant that the fold increase of hepatic ubiquinone 
was higher than observed for cardiolipin (152% and 122% 
vs. respective controls). Because cardiolipin has been sug-
gested to promote electron transport between complex I 
and ubiquinone, it is possible that the disproportionate 
changes in cardiolipin and ubiquinone create an unfavor-
able environment for optimal electron transport (36).
Levels of acylcarnitine were significantly increased in in-
dividuals with NASH, but not in individuals with NAFL, as 
compared with the CTRL group. The accumulation of acyl-
carnitine is suggested to be a sign of mitochondrial stress, 
mitochondrial dysfunction, and impaired FA oxidation 
(37–39). Our results corroborate that acylcarnitine accu-
mulation reflects mitochondrial dysfunction and is a hall-
mark event of NASH. Our data also support the view of 
Koliaki et al. (14), that increased lipid availability in the 
liver stimulates hepatic mitochondrial capacity to protect 
against NAFLD progression. We suggest that levels of car-
diolipin and ubiquinone are increased in individuals with 
NAFLD, in an attempt to boost mitochondrial respiration, 
but that mitochondrial function eventually fails, leading to 
increased levels of acylcarnitine and NASH (Fig. 5). We 
have, however, no measures of mitochondrial function in 
our study and, therefore, it was not possible to directly link 
lipid classes to mitochondrial function. Such possibilities 
will be the focus of future investigations.
We observed a negative association between hepatic odd-
chain PC and NAFLD. Emerging evidence suggests that a 
noticeable portion of odd-chain FA can be derived from 
branched-chain amino acids (BCAAs; i.e., valine, leucine, 
and isoleucine) (40, 41). Because the majority of enzymes 
involved in BCAA catabolism reside in mitochondria (42), 
the odd-chain PC, although of low abundance, is a likely 
indicator of mitochondrial BCAA catabolic capacity. We 
therefore propose that the impairment of BCAA catabolism 
due to hepatic mitochondrial dysfunction may be respon-
sible for the negative association between odd-chain PC 
and NAFLD. In support of this interpretation, Lefort et al. 
(43) previously isolated mitochondria from the skeletal 
muscle of insulin-resistant individuals, and reported spe-
cific abundance differences in proteins involved in BCAA 
oxidation. Specifically, methylmalonate semialdehyde de-
hydrogenase and propionyl-CoA carboxylase, mitochon-
drial proteins that are required for valine and isoleucine 
metabolism before entry into the tricarboxylic acid cycle as 
succinyl-CoA, were decreased in mitochondria of obese in-
dividuals. The authors suggested that this might contribute 
to the accumulation of BCAA that is frequently associated 
with the pathogenesis of insulin resistance (43). Our view-
point is further supported by metabolomic studies showing 
increased hepatic BCAA levels in individuals with NAFLD 
(39, 44, 45). Thus, our study provides new potential expla-
nations regarding the low circulating odd-chain PC and 
high BCAAs observed in NAFLD and type 2 diabetes pa-
tients (46–48).
Although we did not see an increase in ceramide in 
NAFLD, our data do suggest activation of the de novo ce-
ramide biosynthetic pathway, as indicated by progressive 
accumulation of dihydroceramides. This phenomenon is 
possibly a consequence of increased SFAs in NAFLD liver 
(49). A recent study also observed increased levels of dihy-
droceramide species in obese individuals with NASH com-
pared with lean healthy control subjects, and reported a 
positive association between total hepatic dihydroceramide 
levels and hepatic oxidative stress and inflammation (50). 
At the cellular level, increased levels of dihydroceramides 
can regulate autophagy, reactive oxygen species produc-
tion, cell proliferation, and apoptosis (51, 52), which can 
cause fibrosis (52). Thus, there is accumulating evidence 
that increased dihydroceramide may contribute to the pro-
gression of NAFLD and related metabolic disorders.
We also observed increased levels of dihexosylceramide 
in individuals with NASH, but not with NAFL. We previ-
ously reported a positive association between circulating 
dihexosylceramides and alcoholic liver cirrhosis (6), and 
Fig. 5. Schematic presentation of the proposed 
changes in the hepatic lipidome during the progres-
sion of NAFL to NASH: a central role of mitochon-
drial stress and dysfunction. At the early stage of 
NAFLD, there is accumulation of hepatic levels of TG, 
DG, CE, and cardiolipin (CL). This is accompanied by 
changes in the FA composition. Total ubiquinone, 
cholesterol, and dihydroceramide also accumulate at 
this stage. The increase in cardiolipin and ubiquinone 
may serve as a compensatory mechanism to boost mi-
tochondrial respiration. The transition from NAFL to 
NASH is possibly driven by mitochondrial dysfunction, 
resulting in increased levels of dihexosylceramide and 
acylcarnitine. PL, phospholipid.
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increased levels of hepatic dihexosylceramide have been 
detected in human hepatocellular carcinoma tissues 
compared with the surrounding noncancerous hepatic 
tissues (53). Animal studies showed that pharmacological 
inhibitions of glucosylceramide synthase could improve in-
sulin sensitivity and steatosis (54–56). These observations 
provide a strong rationale for further investigation of di-
hexosylceramides in the transition from NAFLD to NASH, 
and possibly hepatocellular carcinoma.
In conclusion, our lipidomic study provides an overview 
of the hepatic lipidome and outlines the putative links be-
tween mitochondrial and cellular lipids and mitochondrial 
dysfunction. We provide clinically relevant information de-
scribing the lipidomic changes during the transition from 
NAFL to NASH. This is important for understanding the 
pathogenesis of this disease. We propose that cardiolipin 
and ubiquinone levels increase in NAFL to enhance mito-
chondrial function, perhaps as a compensatory mechanism 
to reduce steatosis; whereas, the increased levels of acylcar-
nitine in NASH are reflective of mitochondrial dysfunction 
with the progression of disease. The negative association 
between odd-chain PC and NAFLD is another novel find-
ing, which possibly reflects impaired mitochondrial BCAA 
catabolism. The finding of increased dihydroceramides 
and dihexosylceramides with NAFLD provides an intrigu-
ing addition to our understanding of sphingolipid (e.g., 
ceramide) metabolism in NAFLD. Our findings provide 
the clinical rationale to pursue studies aimed at under-
standing the mechanistic relevance of these lipid types in 
NAFLD pathogenesis.
The authors wish to thank Natalie Mellett and Jaquelyn Weir for 
technical support with the lipidomic analysis.
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